Fed. Circ. Won't Revisit Abraxis Loss In Naropin Suit
The Federal Circuit denied Abraxis BioScience Inc.'s bid for an en banc rehearing Monday in its battle with generic-drug maker Navinta LLC over three patents for Abraxis' injectable pain management drug...To view the full article, register now.
Already a subscriber? Click here to view full article